Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 2, 673–682 (1 September 2002) | doi:10.1038/nrc885
Molecular basis of the VHL hereditary cancer syndrome
Abstract
The von Hippel–Lindau hereditary cancer syndrome was first described about 100 years ago. The unusual clinical features of this disorder predicted a role for the von Hippel–Lindau gene (VHL) in the oxygen-sensing pathway. Indeed, recent studies of this gene have helped to decipher how cells sense changes in oxygen availability, and have revealed a previously unappreciated role of prolyl hydroxylation in intracellular signalling. These studies, in turn, are laying the foundation for the treatment of a diverse set of disorders, including cancer, myocardial infarction and stroke.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
